Search Videos and More
News
CD123 Targeted Therapies
CD123 is the alpha subunit of the interleukin 3 (IL-3) receptor. It pairs with a beta subunit, CD131, to transmit cytokine signals from the outside to inside of several types of immune and hematopoietic cells. CD123 is highly expressed on the cell surface of several blood cancers.
News
Dana-Farber Research News 11.01.2025
This twice-monthly newsletter highlights recently published research in which Dana-Farber faculty are listed as first or senior authors. The information is sourced from PubMed, and this issue covers papers published October 1-15.
News
A Brighter Future for B-ALL in Adults
Acute lymphoblastic leukemia (ALL) in adults has been historically associated with dismal clinical outcomes. Fortunately, adults diagnosed with ALL are now more likely to experience a favorable response to treatment due to ongoing improvements in immunotherapy.
News
Bringing Specialists Together: Tandem Leukemia and Stem Cell Transplant Consults
Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a cornerstone of curative therapy for patients with high-risk hematologic malignancies.
News
Acute Myeloid Leukemia Triplet Therapies: Easy as 1, 2, 3
Venetoclax is an oral selective BCL2 inhibitor, which can restore apoptotic activation in leukemia cells that are dependent on this dysregulated pathway, and in combination with azacitidine (Aza/Ven), is an approved and common frontline therapy for patients with acute myeloid leukemia (AML).
News
Menin Inhibitors: A New Class of Anti-Leukemic Agents
A new and potentially broadly applicable class of anti-leukemic agents has arrived on the scene due to preclinical work done in the laboratory of Scott Armstrong, MD, PhD, of Dana-Farber Cancer Institute in collaboration with members of the Adult Leukemia Program within Medical Oncology at Dana-Farber led by Richard Stone, MD, Chief of Staff.
Course
CME: ASH 2025 Highlights
Delivers disease-specific updates from the ASH Annual Meeting to equip hematologists, oncologists, and other clinicians with the knowledge to identify, understand, and apply emerging therapies in the treatment of blood cancers.
Document
Tip Sheet: Caring for Transgender and Gender Diverse Patients
The Breast Oncology Center developed this reference for providers caring for transgender and gender diverse patients in October 2025.
Document
Expert Review: Early Palliative Care as an Adjunct to Disease-Directed Care in Breast Cancer
The Breast Oncology Center developed this reference for providers based on a presentation by James A. Tulsky, MD, given on February 26, 2025.
Video
Paolo Tarantino, MD, PhD, on ADCs
The Next Frontier of Antibody-Drug Conjugate Development - Dana-Farber's Paolo Tarantino, MD, discussed how to optimize the safety of antibody drug conjugates at a session during ESMO25.
Video
FLAURA2 Lung Cancer Study Presented by Pasi Jänne, MD, PhD
Dana-Farber Cancer Institute's Dr. Pasi Jänne details FLAURA2 which found first-line osimertinib + platinum pemetrexed chemotherapy improved overall survival vs. monotherapy in EGFR mutated non-small cell lung cancer, including poorer prognosis patients.
Video
Head and Neck Study Presented by Robert Haddad, MD
Dana-Farber's Dr. Robert Haddad says research shows the combination of a PD1 with anti-LAG3 +/- anti-TIM3 does not improve outcomes in metastatic disease, raising the question of whether to look at this combo earlier, in the neoadjuvant setting.